HOLX Stock Analysis — Hologic
Sector: Healthcare
AI Verdict
At 17.0x next year's earnings with a credible diagnostics moat and 76.6% growth expected, this is cheap for the growth you're getting—if the earnings ramp shows up as forecast.
Competitive Moat
Hologic specializes in women's health diagnostics and medical imaging, with a defensible position built on proprietary technologies in breast and cervical cancer screening. Its installed base of diagnostic platforms and recurring consumables revenue create high switching costs for hospitals and labs.
Summary
A sharp drop in forward P/E to 17.0x, paired with 76.6% expected EPS growth, puts Hologic in the spotlight for value-driven healthcare investors.
Where It Stands
Hologic delivered 2.2% revenue growth and trades at 17.0x forward earnings versus the healthcare sector median of 22x, while the stock's trailing P/E of 30.0x reflects a prior premium now resetting with earnings acceleration.
Key Metrics
- Trailing P/E: 30.0x
- Forward P/E: 17.0x
- PEG Ratio: 0.39
- Earnings Growth: +0.8%
- Revenue Growth: +0.0%
- Market Cap: $17.0B
- 52-Week High: $76.07
- 52-Week Low: $63.19
Analyst Consensus
0 Buy · 20 Hold · 3 Sell (23 analysts)
Bull Case
With analysts forecasting 76.6% EPS growth and a forward P/E of just 17.0x, the stock is cheap for the growth on offer if Hologic's diagnostics moat holds.
Bear Case
If the forward P/E multiple reverts back toward the trailing 30.0x, investors could face a 76% valuation hit unless the 76.6% EPS growth fully materializes.
Catalyst to Watch
Watch for upcoming earnings reports to confirm whether the forecasted EPS surge is tracking, as any miss could quickly erase the current value thesis.